{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:33:54Z","timestamp":1786998834108,"version":"build-2736575974"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background.<\/jats:title>\n                    <jats:p>In pediatric liver transplantation (pLT), follow-up liver biopsies (fLBs) frequently reveal subclinical histological abnormalities, despite normal liver function tests. Findings, including inflammation, fibrosis, and immune-mediated changes, suggest overlapping alloimmune and autoimmune mechanisms with potential long-term consequences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>We performed a prospective, single-center cohort study at the Vall d\u2019Hebron Barcelona Hospital Campus, including 167 children who underwent 299 liver biopsies (214 protocol, 85 post\u2013immunosuppression modification) from 2018 to 2024. Immunosuppression was adjusted according to a preestablished histology-guided protocol, intensifying therapy in patients with subclinical T cell\u2013mediated rejection (S-TCMR; Banff Rejection Activity Index \u22652) detected in protocol biopsies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>\n                      S-TCMR was identified in 71 of 214 (33.2%) protocol biopsies, with fibrosis (Ishak \u22652) in 38 (53.5%). Following protocol-driven immunosuppressive intensification, 57 of 71 (80.3%) achieved S-TCMR resolution at 12 mo, with 8 of 12 showing further improvement at 24 mo. Fibrosis regressed by \u22651 Ishak stage in 21 of 38 (55.3%). Autoantibody responders showed superior S-TCMR (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.006) and fibrosis outcomes (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.05). Donor-specific antibody\u2013positive patients exhibited lower S-TCMR resolution (odds ratio [OR], 3.3;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.1) and a higher risk of persistent fibrosis (OR, 4.8;\n                      <jats:italic toggle=\"yes\">P\u2005<\/jats:italic>\n                      =\u20050.03). Plasma cell\u2013rich S-TCMR (18\/71 [25.4%]) strongly correlated with C4d deposition (5-fold increase) and markedly reduced fibrosis regression (OR, 11.0;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u20050.001), indicating resistance to standard immunosuppression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.<\/jats:title>\n                    <jats:p>Histology-guided, protocol-driven immunosuppression intensification effectively reversed most S-TCMR and fibrosis, underscoring the importance of long-term protocol biopsies for individualized therapy in pLT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/tp.0000000000005721","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T19:00:09Z","timestamp":1777316409000},"page":"e1669-e1678","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Follow-up Liver Biopsy as a Tool for Tailoring Immunosuppressive Treatment in Pediatric Liver Transplantation"],"prefix":"10.1097","volume":"110","author":[{"given":"Jes\u00fas","family":"Quintero-Bernabeu","sequence":"first","affiliation":[{"name":"Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain."},{"name":"Pediatric Hepatology and Liver Transplant Unit, Department of Pediatrics, Vall d\u2019Hebron Hospital Campus, Barcelona, Spain."},{"name":"ERN Rare Liver \u2013 ERN TransplantChild, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Salcedo-Allende","sequence":"additional","affiliation":[{"name":"Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain."},{"name":"Histology Department, Vall d\u2019Hebron Hospital Campus, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Juamperez-Go\u00f1i","sequence":"additional","affiliation":[{"name":"Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain."},{"name":"Pediatric Hepatology and Liver Transplant Unit, Department of Pediatrics, Vall d\u2019Hebron Hospital Campus, Barcelona, Spain."},{"name":"ERN Rare Liver \u2013 ERN TransplantChild, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Mercadal-Hally","sequence":"additional","affiliation":[{"name":"Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain."},{"name":"Pediatric Hepatology and Liver Transplant Unit, Department of Pediatrics, Vall d\u2019Hebron Hospital Campus, Barcelona, Spain."},{"name":"ERN Rare Liver \u2013 ERN TransplantChild, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Padr\u00f3s-Fornieles","sequence":"additional","affiliation":[{"name":"Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain."},{"name":"Pediatric Hepatology and Liver Transplant Unit, Department of Pediatrics, Vall d\u2019Hebron Hospital Campus, Barcelona, Spain."},{"name":"ERN Rare Liver \u2013 ERN TransplantChild, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio","family":"Larrarte-King","sequence":"additional","affiliation":[{"name":"Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain."},{"name":"Pediatric Hepatology and Liver Transplant Unit, Department of Pediatrics, Vall d\u2019Hebron Hospital Campus, Barcelona, Spain."},{"name":"ERN Rare Liver \u2013 ERN TransplantChild, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Mameli","sequence":"additional","affiliation":[{"name":"Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain."},{"name":"Pediatric Hepatology and Liver Transplant Unit, Department of Pediatrics, Vall d\u2019Hebron Hospital Campus, Barcelona, Spain."},{"name":"ERN Rare Liver \u2013 ERN TransplantChild, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Miserachs-Barba","sequence":"additional","affiliation":[{"name":"Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain."},{"name":"Pediatric Hepatology and Liver Transplant Unit, Department of Pediatrics, Vall d\u2019Hebron Hospital Campus, Barcelona, Spain."},{"name":"ERN Rare Liver \u2013 ERN TransplantChild, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Andr\u00e9s","family":"Molino-Gahete","sequence":"additional","affiliation":[{"name":"Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain."},{"name":"Pediatric Surgery Department, Vall d\u2019Hebron Hospital Campus, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Coma-Mu\u00f1oz","sequence":"additional","affiliation":[{"name":"Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain."},{"name":"Pediatric Radiology Department, Vall d\u2019Hebron Hospital Campus, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Moreno-Galdo","sequence":"additional","affiliation":[{"name":"Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain."},{"name":"Pediatric Department, Vall d\u2019Hebron Hospital Campus, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"R1-20260817","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1053\/j.sempedsurg.2017.07.014","article-title":"Pediatric liver transplantation.","volume":"26","author":"Cuenca","year":"2017","journal-title":"Semin Pediatr Surg"},{"key":"R2-20260817","doi-asserted-by":"crossref","first-page":"e13605","DOI":"10.1111\/petr.13605","article-title":"Society of pediatric liver transplantation: current registry status 2011\u20132018.","volume":"24","author":"Elisofon","year":"2020","journal-title":"Pediatr Transplant"},{"key":"R3-20260817","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/MOT.0b013e32834a8caf","article-title":"The long-term liver graft and protocol biopsy: do we want to look? What will we find?","volume":"16","author":"Ekong","year":"2011","journal-title":"Curr Opin Organ Transplant"},{"key":"R4-20260817","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1053\/j.gastro.2018.08.023","article-title":"Evidence of chronic allograft injury in liver biopsies from long-term pediatric recipients of liver transplants.","volume":"155","author":"Feng","year":"2018","journal-title":"Gastroenterology"},{"key":"R5-20260817","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1002\/lt.21549","article-title":"Graft histology characteristics in long-term survivors of pediatric liver transplantation.","volume":"14","author":"Ekong","year":"2008","journal-title":"Liver Transpl"},{"key":"R6-20260817","doi-asserted-by":"crossref","first-page":"6638","DOI":"10.3748\/wjg.v20.i21.6638","article-title":"Protocol liver biopsy is the only examination that can detect mid-term graft fibrosis after pediatric liver transplantation.","volume":"20","author":"Sanada","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R7-20260817","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.clinre.2013.10.009","article-title":"Clinical and histological outcomes following living-related liver transplantation in children.","volume":"38","author":"Dattani","year":"2014","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"R8-20260817","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1002\/hep.22686","article-title":"Graft fibrosis after pediatric liver transplantation: ten years of follow-up.","volume":"49","author":"Scheenstra","year":"2009","journal-title":"Hepatology"},{"key":"R9-20260817","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/hep.21152","article-title":"Progressive histological damage in liver allografts following pediatric liver transplantation.","volume":"43","author":"Evans","year":"2006","journal-title":"Hepatology"},{"key":"R10-20260817","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/lt.23565","article-title":"Low- dose steroids associated with milder histological changes after pediatric liver transplantation.","volume":"19","author":"Kosola","year":"2013","journal-title":"Liver Transpl"},{"key":"R11-20260817","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/lt.23534","article-title":"Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts.","volume":"18","author":"Miyagawa-Hayashino","year":"2012","journal-title":"Liver Transpl"},{"key":"R12-20260817","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/lt.26399","article-title":"Clinical value of surveillance biopsies in pediatric liver transplantation.","volume":"28","author":"Rocque","year":"2022","journal-title":"Liver Transpl"},{"key":"R13-20260817","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/MPG.0000000000003707","article-title":"Protocol biopsies in pediatric liver transplantation recipients improve graft histology and personalize immunosuppression.","volume":"76","author":"Karbaum","year":"2023","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R14-20260817","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/lt.23481","article-title":"Importance of liver biopsy findings in immunosuppression management: biopsy monitoring and working criteria for patients with operational tolerance.","volume":"18","year":"2012","journal-title":"Liver Transpl"},{"key":"R15-20260817","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1002\/hep.31520","article-title":"Efficacy and safety of immunosuppression withdrawal in pediatric liver transplant recipients: moving toward personalized management.","volume":"73","author":"Feng","year":"2021","journal-title":"Hepatology"},{"key":"R16-20260817","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/hep.28681","article-title":"Five-year histological and serological follow-up of operationally tolerant pediatric liver transplant recipients enrolled in WISP-R.","volume":"65","author":"Feng","year":"2017","journal-title":"Hepatology"},{"key":"R17-20260817","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1001\/jama.2011.2014","article-title":"Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants.","volume":"307","author":"Feng","year":"2012","journal-title":"JAMA"},{"key":"R18-20260817","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1002\/lt.25293","article-title":"Long-term survival and cost-effectiveness of immunosuppression withdrawal after liver transplantation.","volume":"24","author":"Manzia","year":"2018","journal-title":"Liver Transpl"},{"key":"R19-20260817","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/LVT.0000000000000780","article-title":"Histological findings in follow-up liver biopsies up to 15 years after pediatric liver transplantation: associations with subclinical rejection, fibrosis, and immunological markers.","volume":"32","author":"Quintero-Bernabeu","year":"2026","journal-title":"Liver Transpl"},{"key":"R20-20260817","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","article-title":"Histological grading and staging of chronic hepatitis.","volume":"22","author":"Ishak","year":"1995","journal-title":"J Hepatol"},{"key":"R21-20260817","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1111\/ajt.13909","article-title":"2016 comprehensive update of the Banff Working Group on liver allograft pathology: introduction of antibody-mediated rejection.","volume":"16","author":"Demetris","year":"2016","journal-title":"Am J Transplant"},{"key":"R22-20260817","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/lt.21444","article-title":"Interface hepatitis is associated with a high incidence of late graft fibrosis in a group of tightly monitored pediatric orthotopic liver transplantation patients.","volume":"14","author":"Herzog","year":"2008","journal-title":"Liver Transpl"},{"key":"R23-20260817","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1002\/lt.24616","article-title":"Late graft hepatitis and fibrosis in pediatric liver allograft recipients: current concepts and future developments.","volume":"22","author":"Kelly","year":"2016","journal-title":"Liver Transpl"},{"key":"R24-20260817","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1097\/TP.0000000000004603","article-title":"Long-term outcome of asymptomatic patients with graft fibrosis in protocol biopsies after pediatric liver transplantation.","volume":"107","author":"Hartleif","year":"2023","journal-title":"Transplantation"},{"key":"R25-20260817","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1097\/TP.0000000000001853","article-title":"Non- HLA antibodies impact on C4d staining, stellate cell activation and fibrosis in liver allografts.","volume":"101","author":"O\u02bcLeary","year":"2017","journal-title":"Transplantation"},{"key":"R26-20260817","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1097\/TP.0000000000000613","article-title":"Donor-specific anti-HLA antibodies and endothelial C4d deposition-association with chronic liver allograft failure.","volume":"99","author":"Iacob","year":"2015","journal-title":"Transplantation"},{"key":"R27-20260817","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1016\/j.ajt.2025.08.004","article-title":"Single-cell transcriptional landscape of liver transplant rejection reveals tissue persistence of clonally expanded, treatment-resistant T cells.","volume":"25","author":"Peters","year":"2025","journal-title":"Am J Transplant"},{"key":"R28-20260817","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ebiom.2016.05.040","article-title":"Progressive fibrosis is driven by genetic predisposition, allo-immunity, and inflammation in pediatric liver transplant recipients.","volume":"9","author":"Varma","year":"2016","journal-title":"EBioMed"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/TP.0000000000005721","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:00:13Z","timestamp":1786996813000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/TP.0000000000005721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000005721","relation":{},"ISSN":["0041-1337","1534-6080"],"issn-type":[{"value":"0041-1337","type":"print"},{"value":"1534-6080","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]}}}